Official and regulatory announcements from Abera Bioscience, including financial reports, clinical trial updates, and material corporate events.
Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that its Board of Directors, based on the authorization granted by the Annual General Meeting held on 11 June 2025, has resolved to carry out a directed share issue of up to
Abera Bioscience, which develops nasal vaccines based on its proprietary technology platform, is in an intensive development phase in which several vaccine candidates are being advanced in parallel towards clinical development. To ensure continued high execution capacity and long-term competence, the Company is now strengthening its organisation through recruitment. The
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT TREDJE KVARTALET 2025 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 919 (3 348) kSEK Resultatet efter finansiella poster uppgick till -835 (-278) kSEK. Resultat per aktie: -0,05 (-0,02) SEK. Soliditeten uppgick till 82 (86) %. FINANSIELL ÖVERSIKT FÖRSTA NIO MÅNADERNA 2025
Abera Bioscience AB (“Abera” or “the Company”) today presents new positive long-term data from a preclinical study of its nasal influenza vaccine candidate. The results show that the vaccine generates strong and long-lasting immune responses both at the mucosal surfaces and systemically, further strengthening confidence in the company’s mucosal vaccine platform
Abera Bioscience AB (“Abera” or the “Company”) has been awarded a £70,000 grant from BactiVac, the Bacterial Vaccines Network. The funding will support studies of the spray applicator intended for use in the upcoming clinical trials of the Company’s pneumococcal vaccine candidate Ab-01.12. The studies will document the performance of
Sammanfattning av delårsrapporten FINANSIELL ÖVERSIKT ANDRA KVARTALET 2025 Nettoomsättningen uppgick till 0 (0) kSEK. Övriga rörelseintäkter uppgick till 4 297 (4 506) kSEK Resultatet efter finansiella poster uppgick till -833 (-665) kSEK. Resultat per aktie: -0,05 (-0,04) SEK. Soliditeten uppgick till 56 (79) %. FINANSIELL ÖVERSIKT FÖRSTA HALVÅRET 2025 Nettoomsättningen uppgick
Abera Bioscience AB (“Abera” or the “Company”) announces the outcome of the directed issue of units that was announced on 17 July 2025. The issue of 1,092,480 units was subscribed to 100 percent. Each unit consists of three (3) shares and one (1) warrant. The subscription price per unit is
Abera Bioscience AB (“Abera” or the “Company”) has been granted an additional approximately SEK 4.7 million (about USD 450,000) from CEPI (the Coalition for Epidemic Preparedness Innovations). The expanded funding will be used to further optimise the development of production processes that enable faster antigen production, as well as to
Abera Bioscience AB (“Abera” or the “Company”), which develops innovative mucosal vaccines to prevent life-threatening diseases, today announces that the Board of Directors has resolved, based on the authorization from the Annual General Meeting held on 11 June 2025, to carry out a directed issue of up to 1,092,480 units.
The 2025 Annual General Meeting (AGM) of Abera Bioscience AB (“Abera” or “the Company”) was held on June 11, 2025. Chairman Anders Ericson delivered an opening address, which is also included further down in this release. The AGM resolved the following: Adoption of the income statement and balance sheetThe AGM